tiprankstipranks
Fate Therapeutics (FATE)
NASDAQ:FATE
US Market
FATE
Fate Therapeutics
RESEARCH TOOLSreports
Want to see FATE full AI Analyst Report?

Fate Therapeutics (FATE) Stock Forecast & Price Target

1,287 Followers
See the Price Targets and Ratings of:

FATE Analyst Ratings

Moderate Buy
7Ratings
Moderate Buy
4 Buy
3 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Fate
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FATE Stock 12 Month Forecast

Average Price Target

$6.70
▲(160.70% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $6.70 with a high forecast of $8.00 and a low forecast of $3.50. The average price target represents a 160.70% change from the last price of $2.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.43,2.8584615384615386,3.286923076923077,3.7153846153846155,4.143846153846154,4.572307692307692,5.000769230769231,5.42923076923077,5.857692307692308,6.286153846153846,6.714615384615385,7.143076923076924,7.571538461538463,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.43,2.7584615384615385,3.086923076923077,3.4153846153846157,3.743846153846154,4.072307692307692,4.400769230769231,4.729230769230769,5.0576923076923075,5.386153846153846,5.714615384615384,6.043076923076923,6.371538461538462,{"y":6.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.43,2.5123076923076924,2.5946153846153845,2.676923076923077,2.7592307692307694,2.8415384615384616,2.9238461538461538,3.006153846153846,3.0884615384615386,3.170769230769231,3.253076923076923,3.3353846153846156,3.417692307692308,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.982,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8.00Average Price Target$6.70Lowest Price Target$3.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on FATE
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$8
Buy
211.28%
Upside
Reiterated
08/17/26
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities
Wells Fargo Analyst forecast on FATE
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$2.5→$3.5
Hold
36.19%
Upside
Assigned
08/14/26
Wells Fargo Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Wedbush Analyst forecast on FATE
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$7
Buy
172.37%
Upside
Reiterated
08/14/26
Wedbush Remains a Buy on Fate Therapeutics (FATE)
Piper Sandler Analyst forecast on FATE
Edward Tenthoff
Piper Sandler
Piper Sandler
$6→$8
Buy
211.28%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE), Satellos Bioscience (NASDAQ: MSLE) and Alumis Inc. (NASDAQ: ALMS)
TD Cowen Analyst forecast on FATE
Tara Bancroft
TD Cowen
TD Cowen
―
Hold
―
Reiterated
08/13/26
Analyst Maintains Hold on Fate Therapeutics as Off‑the‑Shelf CAR‑T Pipeline Advances but Key Efficacy Data Remain Early
Needham Analyst forecast on FATE
Gil Blum
Needham
Needham
―
Hold
―
Reiterated
08/13/26
Analysts Conflicted on These Healthcare Names: Fate Therapeutics (NASDAQ: FATE) and Mediwound (NASDAQ: MDWD)
H.C. Wainwright Analyst forecast on FATE
Robert Burns
H.C. Wainwright
H.C. Wainwright
$7
Buy
172.37%
Upside
Reiterated
07/09/26
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
Bank of America Securities Analyst forecast on FATE
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2→$2.2
Hold
-14.40%
Downside
Reiterated
05/21/26
Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)
Jefferies Analyst forecast on FATE
Roger Song
Jefferies
Jefferies
$4
Buy
55.64%
Upside
Initiated
05/19/26
Fate Therapeutics assumed with a Buy at JefferiesFate Therapeutics assumed with a Buy at Jefferies
Barclays Analyst forecast on FATE
Peter Lawson
Barclays
Barclays
$2
Buy
-22.18%
Downside
Reiterated
10/28/25
Barclays Sticks to Their Buy Rating for Fate Therapeutics (FATE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on FATE
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$8
Buy
211.28%
Upside
Reiterated
08/17/26
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities
Wells Fargo Analyst forecast on FATE
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$2.5→$3.5
Hold
36.19%
Upside
Assigned
08/14/26
Wells Fargo Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Wedbush Analyst forecast on FATE
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$7
Buy
172.37%
Upside
Reiterated
08/14/26
Wedbush Remains a Buy on Fate Therapeutics (FATE)
Piper Sandler Analyst forecast on FATE
Edward Tenthoff
Piper Sandler
Piper Sandler
$6→$8
Buy
211.28%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE), Satellos Bioscience (NASDAQ: MSLE) and Alumis Inc. (NASDAQ: ALMS)
TD Cowen Analyst forecast on FATE
Tara Bancroft
TD Cowen
TD Cowen
―
Hold
―
Reiterated
08/13/26
Analyst Maintains Hold on Fate Therapeutics as Off‑the‑Shelf CAR‑T Pipeline Advances but Key Efficacy Data Remain Early
Needham Analyst forecast on FATE
Gil Blum
Needham
Needham
―
Hold
―
Reiterated
08/13/26
Analysts Conflicted on These Healthcare Names: Fate Therapeutics (NASDAQ: FATE) and Mediwound (NASDAQ: MDWD)
H.C. Wainwright Analyst forecast on FATE
Robert Burns
H.C. Wainwright
H.C. Wainwright
$7
Buy
172.37%
Upside
Reiterated
07/09/26
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
Bank of America Securities Analyst forecast on FATE
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2→$2.2
Hold
-14.40%
Downside
Reiterated
05/21/26
Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)
Jefferies Analyst forecast on FATE
Roger Song
Jefferies
Jefferies
$4
Buy
55.64%
Upside
Initiated
05/19/26
Fate Therapeutics assumed with a Buy at JefferiesFate Therapeutics assumed with a Buy at Jefferies
Barclays Analyst forecast on FATE
Peter Lawson
Barclays
Barclays
$2
Buy
-22.18%
Downside
Reiterated
10/28/25
Barclays Sticks to Their Buy Rating for Fate Therapeutics (FATE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
BLTEBelite Bio, Inc. ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fate Therapeutics

3 Months
Edward TenthoffPiper Sandler
Success Rate
5/11 ratings generated profit
45%
Average Return
-3.83%
Copying Edward Tenthoff's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of -3.83% per trade.
1 Year
Edward TenthoffPiper Sandler
Success Rate
6/11 ratings generated profit
55%
Average Return
+14.06%
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +14.06% per trade.
2 Years
Edward TenthoffPiper Sandler
Success Rate
8/11 ratings generated profit
73%
Average Return
+36.42%
Copying Edward Tenthoff's trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +36.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FATE Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
5
10
11
9
4
Buy
0
0
0
0
0
Hold
5
5
6
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
15
17
14
8
In the current month, FATE has received 4 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. FATE average Analyst price target in the past 3 months is 6.70.
Each month's total comprises the sum of three months' worth of ratings.

FATE Financial Forecast

FATE Earnings Forecast

Next quarter’s earnings estimate for FATE is -$0.27 with a range of -$0.31 to -$0.24. The previous quarter’s EPS was -$0.25. FATE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year FATE has Performed in-line its overall industry.
Next quarter’s earnings estimate for FATE is -$0.27 with a range of -$0.31 to -$0.24. The previous quarter’s EPS was -$0.25. FATE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year FATE has Performed in-line its overall industry.

FATE Sales Forecast

Next quarter’s sales forecast for FATE is $1.17M with a range of $0.00 to $2.50M. The previous quarter’s sales results were $2.08M. FATE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year FATE has Performed in-line its overall industry.
Next quarter’s sales forecast for FATE is $1.17M with a range of $0.00 to $2.50M. The previous quarter’s sales results were $2.08M. FATE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year FATE has Performed in-line its overall industry.

FATE Stock Forecast FAQ

What is FATE’s average 12-month price target, according to analysts?
Based on analyst ratings, Fate Therapeutics’s 12-month average price target is 6.70.
    What is FATE’s upside potential, based on the analysts’ average price target?
    Fate Therapeutics has 160.70% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is FATE a Buy, Sell or Hold?
          Fate Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Fate Therapeutics’s price target?
            The average price target for Fate Therapeutics is 6.70. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $8.00 ,the lowest forecast is $3.50. The average price target represents 160.70% Increase from the current price of $2.57.
              What do analysts say about Fate Therapeutics?
              Fate Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of FATE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.